rand. Phase III, double-blinded, multicenter study to evaluate safety/efficacy of neoadjuvant treatment with atezolizumab or placebo in combination with platinum-based chemo in patients with resectable stage IB−IIIA NSCLC

This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.